ATAI Life Sciences N.V.

Research ATAI Life Sciences N.V. (ATAI) on Bullrun: market cap USD 1.97B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerATAI
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 1.97B
• Financial periodFY2025
• RevenueUSD 4.09M
• Revenue growth1227.6%
• Net income-USD 660.05M
• Free cash flow-USD 103.58M

Valuation Snapshot

latest market cap is USD 1.97B.

About ATAI Life Sciences N.V.

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder;

Frequently asked questions

What is ATAI Life Sciences N.V.'s market cap?

ATAI Life Sciences N.V.'s market capitalization is USD 1.97B.

What does ATAI Life Sciences N.V. do?

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada.